Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
January 13, 2015
Assignee:
Biogen Idec MA Inc.
Inventors:
Sha Mi, John McCoy, R. Blake Pepinsky, Daniel H. S. Lee
Abstract: An outdoor umbrella includes an awning frame, a supporting shaft and an adjustable rotation base including a base housing and a transportation arrangement. The base housing is arranged to couple with the supporting shaft to support the awning frame in an upright manner, and includes a plurality of transferring wheels. The transportation arrangement is provided at the base housing to operate the base housing between an idle mode and a transportation mode, wherein in the idle mode, the transferring wheels are suspenedly lifted up to position above the bottom edge of the base housing such the base housing is sat on the ground surface in a stationary manner, wherein in the transportation mode, the base housing is lifted up by air pressure for allowing the transferring wheels to move out of the receiving cavity at a position below the bottom edge of the base housing.
Abstract: In one aspect, the disclosure provides methods for using NMR and NIR to evaluate biological samples. In some embodiments, the methods include a step of performing a Nuclear Magnetic Resonance (NMR) analysis on a sample to obtain an NMR spectrum, a step of performing a Near Infrared Spectroscopy (NIR) analysis on the sample to obtain an NIR spectrum, and/or a step of performing a data fusion analysis to evaluate the NIR spectrum.
Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
Type:
Grant
Filed:
September 6, 2012
Date of Patent:
December 2, 2014
Assignee:
Biogen Idec Ma Inc.
Inventors:
David J. Burke, Shaun E. Buckley, Sherwood Russ Lehrman, Barbara Horsey O'Connor, James Callaway, Christopher P. Phillips
Abstract: The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides.
Abstract: The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist.
Type:
Grant
Filed:
July 5, 2013
Date of Patent:
November 25, 2014
Assignee:
Biogen Idec MA Inc.
Inventors:
Sha Mi, Kenneth J. Rhodes, R. Blake Pepinsky
Abstract: The present invention features inter alia polypeptides comprising heterodimeric Fc regions. In addition, the instant invention provides methods for treating or preventing a disease or disorder in subject by administering the polypeptides of the invention to said subject.
Type:
Application
Filed:
July 13, 2012
Publication date:
November 20, 2014
Applicant:
BIOGEN IDEC MA INC.
Inventors:
Frederick R. Taylor, Justin A. Caravella, Alexey A. Lugovskoy, Amna Saeed-Kothe, Ellen A. Garber
Abstract: The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.
Type:
Grant
Filed:
August 17, 2007
Date of Patent:
November 18, 2014
Assignee:
Biogen Idec MA Inc.
Inventors:
Scott Glaser, Stephen Demarest, Brian Robert Miller, William B. Snyder, Xiufeng Wu, Norman Wang, Lisa J. Croner, Alexey Alexandrovich Lugovskoy
Abstract: Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate.
Abstract: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.
Type:
Application
Filed:
March 26, 2014
Publication date:
October 30, 2014
Applicant:
Biogen Idec MA Inc.
Inventors:
Anthony Rossomando, R. Blake Pepinsky, BangJian Gong
Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.
Type:
Grant
Filed:
September 23, 2011
Date of Patent:
October 28, 2014
Assignee:
Biogen Idec MA Inc.
Inventors:
Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
Type:
Application
Filed:
June 17, 2014
Publication date:
October 16, 2014
Applicant:
BIOGEN IDEC MA INC.
Inventors:
Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Ma Bin, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
Abstract: The present invention provides a formulation of a Factor VIII polypeptide, e.g., FVIII-Fc, and methods of using the same. The FVIII polypeptide can be a recombinant FVIII protein, a short-acting FVIII protein, or a long-acting FVIII protein. The pharmaceutical formulation comprising a FVIII polypeptide can be used for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of hemophilia.
Type:
Application
Filed:
March 14, 2014
Publication date:
October 16, 2014
Applicant:
Biogen Idec MA Inc.
Inventors:
Kevin MALONEY, Daniel Gage, Ahmad Abdul-Fattah
Abstract: Provided are pro-coagulant compounds (e.g., pro-coagulant peptides or peptide derivatives) and methods of using and making those compounds. Further provided are conjugates between a pro-coagulant compound of the present disclosure (e.g., pro-coagulant peptide or peptide derivative) and a polypeptide selected from FIX, FVIIa, FVIII, and platelet targeting moieties (e.g., PDG-13), wherein the compound is linked to the polypeptide optionally via a linker. The compounds and conjugates are useful for the treatment of coagulation disorders, such as hemophilia A and hemophilia B. Further provided are methods of using and making the conjugates.
Type:
Application
Filed:
June 9, 2012
Publication date:
October 9, 2014
Applicant:
Biogen IDEC MA Inc.
Inventors:
Karina Thorn, Garabet G. Toby, Adam R. Mezo
Abstract: A method for operating a lighting system includes the steps of a) illuminating a stage with light from at least one light source; b) recording a portion of the stage with the video camera and generating digital video signals; c) transmitting the digital video signals to a video conversion device; d) converting the video signals into digital image data signals; e) transmitting the digital image data signals to the digital memory of the lighting control console; f) starting a display task in the digital processor of the lighting control console, in order to process the image data signals for displaying the same at the display of the lighting control console; and g) graphically representing a portion of the stage by displaying the image data signals which have been processed in the digital processor at the display of the lighting control console.
Abstract: An outdoor umbrella includes an awning frame, a supporting shaft and an adjustable rotation base including a base housing and a transportation arrangement. The base housing is arranged to couple with the supporting shaft to support the awning frame in an upright manner, and includes a plurality of transferring wheels. The transportation arrangement is provided at the base housing to operate the base housing between an idle mode and a transportation mode, wherein in the idle mode, the transferring wheels are suspenedly lifted up to position above the bottom edge of the base housing such the base housing is sat on the ground surface in a stationary manner, wherein in the transportation mode, the base housing is lifted up by air pressure for allowing the transferring wheels to move out of the receiving cavity at a position below the bottom edge of the base housing.